(NASDAQ: DNTH) Dianthus Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 4.11%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16%.
Dianthus Therapeutics's earnings in 2025 is -$100,732,000.On average, 9 Wall Street analysts forecast DNTH's earnings for 2025 to be -$110,308,738, with the lowest DNTH earnings forecast at -$124,780,730, and the highest DNTH earnings forecast at -$100,339,144. On average, 8 Wall Street analysts forecast DNTH's earnings for 2026 to be -$114,611,744, with the lowest DNTH earnings forecast at -$158,227,111, and the highest DNTH earnings forecast at -$90,691,149.
In 2027, DNTH is forecast to generate -$116,686,063 in earnings, with the lowest earnings forecast at -$145,041,519 and the highest earnings forecast at -$93,585,548.